Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma; it features extreme molecular heterogeneity regardless of the classical cell-of-origin (COO) classification. Despite this, the standard therapeutic approach is still immunochemotherapy (rituximab plus cyclophosphamide, do...
Main Authors: | Nicoletta Coccaro, Luisa Anelli, Antonella Zagaria, Tommasina Perrone, Giorgina Specchia, Francesco Albano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/1/185 |
Similar Items
-
Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies
by: Nicoletta Coccaro, et al.
Published: (2020-04-01) -
The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
by: Matias Mendeville, et al.
Published: (2022-10-01) -
A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
by: Chung C
Published: (2022-08-01) -
Primary diffuse large B-cell lymphoma at gastrojejunostomy site: A rare case report
by: Shruthi, et al.
Published: (2023-01-01) -
Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity?
by: Johanna Vets, et al.
Published: (2023-04-01)